Nanogen s Q2 Revenues Slump, CF Test Launch Is Delayed | GenomeWeb

For electronic hybridization chip maker Nanogen, the second quarter was not exactly charged with excitement. The company reported total revenues of $2 million for the quarter, down from $2.7 million year over year, and announced that the much-awaited commercial launch of its analyte-specific reagent (ASR) test for cystic fibrosis had been delayed a quarter. As a result of this delay, Nanogen also revised its 2002 revenue forecast downward to $7-$10 million, from an initial projection of $10-$13 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.